Natural History of Obesity Subphenotypes: Dynamic Changes Over Two Decades and Prognosis in the Framingham Heart Study.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 03 2019
Historique:
received: 18 06 2018
accepted: 15 10 2018
pubmed: 20 10 2018
medline: 18 12 2019
entrez: 20 10 2018
Statut: ppublish

Résumé

The natural histories of obesity subphenotypes are incompletely delineated. To investigate dynamic changes in obesity subphenotypes and associations with outcomes. Framingham Offspring Cohort participants (n = 4291) who attended the examination cycles 2 (1979 to 1983) to 7 (1998 to 2001), which included 26,508 participant observations. Obesity subphenotypes [metabolically healthy nonobese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy nonobese (MUNO), and metabolically unhealthy obese (MUO)] were ascertained based on metabolic health (<2 Adult Treatment Panel III criteria). The outcomes were subclinical cardiovascular disease (CVD), incident diseases [diabetes, hypertension, chronic kidney disease (CKD), CVD], and all-cause mortality. At baseline, 4% and 31% of participants exhibited the MHO and MUNO subphenotypes, respectively. Four-year probability of MHO participants becoming MUO was 43% in women and 46% in men. Compared with MHNO, MHO participants had 1.28-fold (95% CI, 0.85 to 1.93) and 1.92-fold (95% CI, 1.38 to 2.68) higher odds of subclinical CVD and coronary artery calcification, respectively; corresponding values for MUNO were 1.95 (1.54 to 2.47) and 1.92 (1.38 to 2.68). During follow-up (median of 14 years), 231 participants developed diabetes, 784 hypertension, 423 CKD, 639 CVD, and 1296 died. Compared with MHNO, MHO conferred higher risks of diabetes [hazard ratio (HR), 4.69; 95% CI, 2.21 to 9.96] and hypertension (HR, 2.21; 95% CI, 1.66 to 2.94). Compared with MUO, MHO conferred lower risks of diabetes (0.21; 0.12 to 0.39), CVD (0.64; 0.43 to 0.95), and CKD (0.44; 0.27 to 0.73), but similar hypertension, cardiovascular mortality, and overall mortality risks. Over time, most MHO participants developed metabolic abnormalities and clinical disease. The MHO subphenotype is a harbinger of future risk.

Identifiants

pubmed: 30339231
pii: 5134201
doi: 10.1210/jc.2018-01321
pmc: PMC6349002
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

738-752

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268201500001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL107385
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL125232
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201500001I
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL093328
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC25195
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126136
Pays : United States

Références

N Engl J Med. 2017 Nov 30;377(22):2145-2153
pubmed: 29171811
Obesity (Silver Spring). 2012 Mar;20(3):651-9
pubmed: 21799477
J Am Coll Cardiol. 2015 Jan 6;65(1):101-102
pubmed: 25572516
Mayo Clin Proc. 2014 Mar;89(3):335-45
pubmed: 24582192
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Eur Heart J. 2015 Mar 1;36(9):551-9
pubmed: 24670711
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Int J Epidemiol. 2012 Jun;41(3):805-17
pubmed: 22467292
Ann Intern Med. 2017 May 2;166(9):628-636
pubmed: 28384781
Obesity (Silver Spring). 2014 Nov;22(11):2420-5
pubmed: 25131796
Diabetes Care. 2015 Nov;38(11):2177-87
pubmed: 26494809
Am J Epidemiol. 1979 Sep;110(3):281-90
pubmed: 474565
Diabetes Care. 2013 Aug;36(8):2294-300
pubmed: 23637352
Obesity (Silver Spring). 2008 Feb;16(2):463-9
pubmed: 18239660
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Circulation. 2010 Jan 19;121(2):230-6
pubmed: 20038741
Ann Intern Med. 2016 Mar 1;164(5):305-12
pubmed: 26857595
Int J Obes (Lond). 2017 Jan;41(1):170-177
pubmed: 27748744
JAMA Intern Med. 2014 Jan;174(1):15-22
pubmed: 24217719
Diabetes Care. 2009 Dec;32(12):2297-9
pubmed: 19729521
Int J Obes (Lond). 2015 Mar;39(3):514-9
pubmed: 25287753
Eur J Endocrinol. 2015 Nov;173(5):703-8
pubmed: 26286585
J Am Coll Cardiol. 2014 Jun 24;63(24):2679-86
pubmed: 24794119
JAMA. 2016 Jun 7;315(21):2284-91
pubmed: 27272580
Stat Med. 1988 Jan-Feb;7(1-2):205-22
pubmed: 3353604
Lancet Diabetes Endocrinol. 2013 Oct;1(2):152-62
pubmed: 24622321
Eur Heart J. 2013 Feb;34(5):389-97
pubmed: 22947612
Obes Rev. 2014 Sep;15(9):697-708
pubmed: 25059108
Eur J Prev Cardiol. 2016 Jun;23(9):956-66
pubmed: 26701871
J Am Soc Nephrol. 2002 Apr;13(4):1034-9
pubmed: 11912263
Int J Obes (Lond). 2011 Jul;35(7):971-81
pubmed: 20975726
Diabetes. 2007 Jun;56(6):1718-26
pubmed: 17369522
Ann Intern Med. 2013 Dec 3;159(11):758-69
pubmed: 24297192
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Coll Cardiol. 2017 Sep 19;70(12):1429-1437
pubmed: 28911506
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
J Clin Endocrinol Metab. 2012 Jul;97(7):2482-8
pubmed: 22508708
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Am J Cardiol. 2008 Nov 1;102(9):1136-41, 1141.e1
pubmed: 18940279
J Clin Invest. 1997 Sep 1;100(5):1166-73
pubmed: 9303923
Eur Heart J. 2018 Feb 1;39(5):397-406
pubmed: 29020414

Auteurs

Justin B Echouffo-Tcheugui (JB)

Division of Endocrinology, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.
National Heart, Blood and Lung Institute, Framingham Heart Study, Framingham, Massachusetts.

Meghan I Short (MI)

Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.

Vanessa Xanthakis (V)

National Heart, Blood and Lung Institute, Framingham Heart Study, Framingham, Massachusetts.
Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.

Patrick Field (P)

Department of Medicine, Internal Medicine Residency Program, Boston University School of Medicine, Boston, Massachusetts.

Todd R Sponholtz (TR)

Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.

Martin G Larson (MG)

National Heart, Blood and Lung Institute, Framingham Heart Study, Framingham, Massachusetts.
Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.

Ramachandran S Vasan (RS)

National Heart, Blood and Lung Institute, Framingham Heart Study, Framingham, Massachusetts.
Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.
Section of Cardiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH